Orphazyme files registration statement in the U.S. in connection with proposed global offering, consisting of initial public offering of ADSs in the U.S. and concurrent private placement of ordinary shares in Europe

by | Sep 7, 2020

Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed registered initial public offering of the Company’s ordinary shares, to be delivered in the form of American Depositary Shares in the United States, as well as a concurrent private placement of ordinary shares to certain qualified investors in Europe. 


Press inquiries should be adressed to:

Sten Verland, PhD MSc

General Partner